Compare IDEXX Laboratories, Inc. (IDXX) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Procter & Gamble Co — how do they compare? IDEXX Laboratories, Inc. trades at $572 (market cap $46.22B), while Procter & Gamble Co trades at $144.37 (market cap $337.53B). The key difference: Procter & Gamble Co is far larger — about 7.3× IDEXX Laboratories, Inc.'s market cap, and Procter & Gamble Co pays a 3% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | PG | |
|---|---|---|
Market Cap | $46.22B | $337.53B |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $167.18 |
52-Week Low | $526.44 | $138.10 |
Enterprise Value | $47.12B | $363.37B |
Volume | — | 6,423,436 |
Dividend Yield | — | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Procter & Gamble (PG) trades at $146.38, up 0.42% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at 1.9. Revenue for 2025 reached $84.28B, with a net income margin of 18.44%, while valuation ratios like P/E of 21.94 and P/S of 4.04 indicate a premium. Recent news highlights PG's dividend reliability and supply chain improvements.
PG offers steady growth and income appeal, supported by a 69-year dividend growth streak and analyst consensus price target of $161.20. Risks include premium valuation pressures and soft demand concerns. The stock's outlook hinges on execution of Supply Chain 3.0 initiatives and ability to maintain margins amid economic volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
